ArticleNature communications2020

Combating acquired resistance to MAPK inhibitors in melanoma by targeting Abl1/2-mediated reactivation of MEK/ERK/MYC signaling.

Rakshamani Tripathi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.